The guidance addresses implementation of amendments made by the FDA Reauthorization Act of 2017.
FDA published final guidance on May 24, 2021 for the early planning of pediatric evaluation of molecularly targeted oncology drugs as required by section 505B(a)(1)(B) of the Federal Food, Drug, & Cosmetic Act (FD&C), as amended by the FDA Reauthorization Act of 2017 (FDARA). The guidance document addresses molecularly targeted oncology drugs where original New Drug Applications (NDAs) and Biologics License Applications (BLAs) are submitted to FDA. FDA expects early pediatric evaluation of these drugs to accelerate the creation of a pediatric development plan and development of pediatric oncology drugs.
Specifically, the document discusses regulatory considerations such as molecular target, determination of relevance, target lists, recommended studies, and rare cancers. It also addresses international collaboration in development of these drugs.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.